Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

Background: Nexvax2® is a novel, peptide-based, epitope-specific immunotherapy intended to be administered by regular injections at dose levels that increase the threshold for clinical reactivity to natural exposure to gluten and ultimately restore tolerance to gluten in patients with celiac disease...

Full description

Bibliographic Details
Main Authors: A. James M. Daveson, Hooi C. Ee, Jane M. Andrews, Timothy King, Kaela E. Goldstein, John L. Dzuris, James A. MacDougall, Leslie J. Williams, Anita Treohan, Michael P. Cooreman, Robert P. Anderson
Format: Article
Language:English
Published: Elsevier 2017-12-01
Series:EBioMedicine
Subjects:
Celiac disease
Nexvax2
Immunotherapy
T cell
Peptide
Randomized controlled trial
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396417304619

Similar Items

Similar Items